Notice of special administration instructions for Zemaira. Read more here X


Encompassing support for alpha-1 antitrypsin deficiency.

Alpha-1 information and Zemaira treatment support

CSL Behring, the maker of Zemaira, understands that Alpha-1 patients have needs that go beyond treatment, which is why the Zemaira CareZ program was created. Zemaira CareZ (pronounced “cares”) is a unique community of people and services focused on providing the assistance and support you need to live with Alpha-1 and stay on your Zemaira therapy.

Starting Zemaira
Simplifies the process of getting started on therapy with Zemaira.

Affording Zemaira
Provides expert assistance in dealing with issues related to health insurance coverage and managing the cost of therapy.

Connecting With Alphas
Puts you in touch with other Alphas and resources that can help you manage the day-to-day of living with Alpha-1.

Maintaining Your Health
Provides information and opportunities to adopt a healthier lifestyle.

Make sure you are enrolled in Zemaira CareZ

All patients being treated with Zemaira are eligible for CareZ. To enroll or confirm your enrollment status, call 1-866-ZEMAIRA (1-866-936-2472). You can also complete and submit the enrollment form.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR03-13-0022(3) 6/2015